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Background 
Secondary leukemia and myelodysplastic syndromes have been reported in patients 
following treatment for a wide range of neoplastic disorders. However, second 
malignancies after chemotherapy and/or irradiation for osteosarcoma are unusual. 
 
Procedure 
We report the case of a 15-year-old girl who developed a myelodysplastic syndrome 
with evolution to acute nonlymphocytic leukemia after treatment for osteosarcoma. 
Therapy-related acute leukemia karyotype findings such as abnormalities of 
chromosomes 5, 7, and 17 were found in the cytogenetic analysis. Moreover, using 
denaturing gradient gel electrophoresis and DNA sequencing, we detected the presence 
of a double germline mutation in exon 7 of the TP53 gene. 
 
Conclusion 
This observation supports the possibility of a causal relationship between germline 
TP53 mutations and the development of secondary leukemia and myelodysplasia. 
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INTRODUCTION 
 
Among children diagnosed with cancer nowadays, 70% will be long-term survivors. 
This fact makes secondary malignant neoplasms the most serious complication of 
cancer therapy [1]. In past years, several groups have reported acute leukemia in 
children as a complication of chemotherapy and radiation regimens [2,3]. However, the 
development of leukemia after treatment for osteosarcoma has rarely been recorded 
[4,5]. 
 
Although exposure to DNA damaging agents can contribute to the emergence of 
neoplastic disease, identification of tumor genetic changes through cytogenetic and 
molecular procedures suggests a genetic component in the development of human 
cancer. The TP53 gene, located on the short arm of chromosome 17, is a tumor 
suppressor gene whose product plays a key role in neo-plastic transformation [6]. TP53 
gene mutations are generally missense changes involving almost exclusively exons 4 
through 8 [7]. These mutations, either de novo or inherited, result in a protein with 
increased stability and prolonged half-life that can lead to cellular transformation. An 
increased incidence of TP53 gene aberrations and abnormalities of chromosome 17 has 
been reported in children and young adults with second malignant neoplasms [8]. We 
describe a case of acute nonlymphocytic leukemia preceded by a myelodysplastic phase 
after chemo- and radiotherapy administration to a TP53 double mutation carrier girl 
with chondroblastic osteosarcoma. 
 
 
 
CASE REPORT 
 
A 15-year-old girl was diagnosed with nonmetastatic chrondroblastic osteosarcoma of 
the middle third of the right femur in February 1989. No family history of cancer was 
reported. She received neoadjuvant chemotherapy with 3 courses of methotrexate 12 
g/m2, vincristine 1.75 mg/m2 and doxorubicin 90 mg/m2. Simultaneously, she was 
treated with 3 cycles of intra-arterial carboplatin at 150 mg/m2 × 3 days administered at 
3 week intervals. A limb salvage procedure with tumor resection and a functional 
reconstruction using bone graft was performed in April 1989. Histopathologic studies of 
the resected specimen demonstrated less than 20% tumor necrosis. Both intra- and 
postoperative radiotherapy of the tumor bed and surrounding tissues were performed at 
total doses of 20 Gy and 46 Gy respectively. Chemotherapy administered during the 
postoperative period included 6 courses of methotrexate 10 g/m2/week every fourth 
week, and 7 courses of doxorubicin 50 mg/m2, carboplatin 100 mg/m2 and cisplatin 40 
mg/m2. During this time, the patient also received a cycle with ifosfamide 4,5 g/m2, 
dactinomycin 1,8 mg/m2 and bleomycin 30 mg/m2. Total duration of therapy was 10 
months. The patient remained well until October 1992 when local recurrence in the right 
proximal femur was documented and limb amputation was performed. No further 
treatment was applied until November 1993 when she developed a lung metastasis and a 
mass on the left femoral condyle that after biopsy was found to be an osteogenic 
sarcoma. Surgical excision of the lung metastasis and tumor resection of the knee with 
replacement by a prosthesis were performed. Between December 1993 and October 
1994 she received 10 additional courses of chemotherapy with methotrexate at high 
doses 15 g/m2, carboplatin 600 mg/m2 and etoposide 400 mg/m2. In March 1995 a new 
single lung metastasis was resected. Six months later a local recurrence in the soft 
tissues of the left knee and another single lung metastasis were found, both of them 
requiring surgical treatment. No chemotherapy or radiotherapy were performed after 
these surgical treatments. 
 
In December 1995 persistent anemia and thrombocytopenia were noted. Blood count 
showed: hemoglobin, 75 g/L; leukocytes, 7,3 x 109/L, (myelocytes 7%, meta-
myelocytes 13%, neutrophils 21%, basophils 1%, lymphocytes 51%, monocytes 4%, 
blasts 3%); platelets 23 x 109/L. Bone marrow aspirate was consistent with refractory 
anemia with excess blasts, and treatment with low-dose cytarabine was performed 
during 15 days. A new bone marrow aspirate at the end of treatment showed 
progression to acute nonlymphocytic leukemia. Complete remission was attained after 
induction with intensive chemotherapy consisting of idarubicin 10 mg/m2 x 3 days, 
cytarabine 100 mg/m2 x 10 days and etoposide 100 mg/m2 x 5 days, and consolidation 
with a cycle of mitoxantrone 12 mg/m2 x 3 days and cytarabine 1 g/m2 x 6 days. The 
patient underwent allogeneic peripheral blood progenitor cells transplantation from her 
HLA-identical sister. The conditioning regimen consisted of busulfan 4 mg/kg x 4 days 
and cyclophosphamide 60 mg/kg x 2 days; cyclosporine A and methotrexate were given 
as prophylaxis for graft-versus-host disease. Successful engraftment, defined as an 
absolute neutrophil count greater than 0,5 x 109/L, was achieved on day +14. The 
platelet count was greater than 50 x 109/L on day +18. A bone marrow aspirate 
performed on day +46 showed no blast cells but she relapsed on day +104. Acute renal 
failure developed on day +130. Her condition deteriorated further and the patient died 
on day +132. 
 
 
 
MOLECULAR ANALYSIS 
 
One tissue sample from the lung metastasis resected in March 1995, another from 
peripheral blood lymphocytes at that time, and another one from bone marrow at 
diagnosis of acute leukemia were obtained to perform the molecular analyses. Genomic 
DNA was obtained by isolation and purification with proteinase K and extraction using 
conventional phenolchloroform procedures both in the case of peripheral lymphocytes, 
fresh tumor tissue and bone marrow [9]. Screening for mutations at exons 5 through 8 
of the TP53 gene was performed as previously described [10,11]. In brief, 300 ng of 
genomic DNA were amplified in a 50 µl PCR reaction (polymerase chain reaction) 
containing 20 pmol of each primer, 200 µM dNTPs, 20 mM Tris-HCl (pH 8.5), 16 mM 
(NH4)2SO4, 2.5 mM MgCl2, 150 µ,g/ml BSA, and 1,5 units of Taq DNA polymerase 
(BioTaq, Bioprobe Systems). DNA samples were analyzed by denaturing gradient gel 
electrophoresis (DGGE) [12]. Samples were loaded onto 12% or 6,5% polyacrylamide 
gels (acrylamide:bisacrylamide 37,5:1) containing the appropriate denaturant gradient 
(100% denaturant corresponds to 7 M urea and 40% deionized formamide). Sequences 
of primers, PCR conditions, gradient concentrations and running conditions for each 
TP53 exon were those described by Børresen and coworkers for exons 5, 7 and 8 and by 
Hamelin and coworkers for exon 6 [10,11]. Bands with altered electrophoretic 
mobilities corresponding to TP53 exon 7 were cycle sequenced using the Thermo 
Sequenase Cycle Sequencing kit (Amersham Life Science). 
 
The sequencing of the DNA extracted from the metastasis, the peripheral blood 
lymphocytes and the bone marrow blasts carried a double mutation (Figure 1): one of 
the alleles (allele 1) had a frameshift mutation originated by the deletion of a cytosine, 
and the other one (allele 2) a missense tandem mutation CC to TT that changed the wild 
type proline into a phenylalanine in the codon 250 of the protein. 
 
 
 
CYTOGENETIC STUDIES 
 
Cytogenetic studies were performed on bone marrow cells using 24-hour cultures and 
G-banding. A minimum of 30 well-spread metaphases were analysed from each case. 
Karyotypes were described according to the International System for Human 
Cytogenetic Nomenclature (ISCN) [13]. 
 
Cytogenetic analysis of bone marrow obtained at the time of diagnosis of 
myelodysplastic syndrome showed normal metaphases in 1 of 35 (3%) and four 
abnormal clones 43,XX,t(3;6) (q21;p21),-5,-17,-18 (17% metaphases); 43,XX,t(3;6) 
(q21;p21),-5,-17,-18,del(22)(q11) (25% metaphases); 45,XX,t(3;6)(q21;p21),del(5)  
(q13q32),-7,-17,-18,+del(22)(q11),+mar(50%metaphases);85–90,XXX,t(3;6) (q21;p21), 
inc (7% metaphases). A partial karyotype illustrating the t(3;6) is shown in Figure 2. A 
new cytogenetic study was performed after the treatment with low-dose cytarabine, at 
diagnosis of nonlymphocytic leukemia. Besides previous findings, a new clone was 
detected: 43,XX, t(3;6) (q21;p21), -5,der(7)t(7;?)(q34;?),-17,-18,del(22)(q11) (2% 
metaphases). 
  
After induction and consolidation therapy both morphologic and cytogenetic remissions 
were achieved. A normal female karyotype was shown in all 52 metaphases analyzed. A 
new cytogenetic study was performed after the allogeneic peripheral blood progenitor 
cell transplantation. No abnormal clones were detected. When relapse was observed, the 
cytogenetic analysis showed normal metaphases in 24 of 37 (65%) and two abnormal 
hypodiploid clones. 43,XX,t(3;6)(q21;p21),-5, -17,-18 (27% metaphases);  45,XX,t(3;6) 
(q21;p21), del(5)(q13q32), der(7)t(7;?) (q34;?),-7,-17,-18,+del(22) (q11),+mar (8% 
metaphases). 
  
 
 
DISCUSSION 
 
TP53 is a tumor suppressor gene located on the short arm of human chromosome 17 
that encodes a nuclear phosphoprotein that functions as a negative regulator of cell 
proliferation. Mutations in this gene have been associated with many human tumours 
including osteosarcomas. The development of osteosarcoma is a result of the loss of 
normal p53, which then releases bone cells from p53 suppression of neoplastic growth 
[14,15]. Mutation of TP53, followed by a loss of the remaining wild type allele, usually 
by deletion, may inactivate that gene and determine the emergence of cell 
transformation. In our patient, the mutations were present both in the tumour as well as 
in the germline, but samples from her parents were not available, so that we cannot be 
sure of the real significance and possible inheritance of the mutations. The presence of 
two TP53 mutated alleles has as a consequence the absence of wild type p53 protein. 
Given the key role of the p53 protein in the cell cycle progression and the suppression 
of abnormal cell growth, we are able to better understand the malignant behaviour of the 
osteosarcoma and its aggressive progression in our patient [16]. Although these 
mutations have already been described in the literature, they have never been reported, 
to our knowledge, in the same patient [17]. 
 
Therapy-related second malignancies have been identified in patients receiving 
radiotherapy, prolonged chemotherapy regimes or combined modality therapy for a 
variety of primary neoplasms. With the advances in treatment of childhood cancer, more 
children are surviving for longer periods of time and the possibility of developing a 
second malignancy has become an important concern [18]. Although second 
malignancies following therapy for osteosarcoma are unusual, its treatment has been 
related to development of breast cancer, esophageal carcinoma and soft tissue sarcoma 
[1,19,20]. An increased incidence of TP53 mutations has been recently reported in 
children diagnosed with osteosarcoma and second cancers [8]. 
 
Secondary leukemia represents 20% of all second neoplasms following chemotherapy 
and has been reported in patients treated for a wide range of primary malignant tumours 
[21]. However, it is rarely observed in patients with osteosarcoma [4,5,22–28]. The 
main risk factor in the development of secondary leukemia seems to be treatment with 
alkylating agents, cisplatin and epipodo-phyllotoxins whose cytotoxic activity is 
induced by a p53-dependent apoptotic cell death program [29–31]. Although 
radiotherapy could be a factor in the development of subsequent leukemia, there is no 
evidence that such radiotherapy to the involved field contributes to the emergence of 
this type of leukemia [25,29]. A genetic component expressed as host susceptibility 
could enhance the effect of all these risk factors. Decreased cell death caused by 
exposure to DNA-damaging chemo-therapy and irradiation could be the way in which 
TP53 mutations contribute to leukemogenesis [32]. The case we report here occurred 
following treatment with several drugs, including high cumulative amounts of 
carboplatin, cisplatin and etoposide, and small amounts of alkylating agents, such as 
ifosfamide. As this patient had been exposed to multiple chemotherapy agents, it is 
difficult to assign the cause of the secondary leukemia to a specific drug. The addition 
of radiotherapy to the involved area probably did not contribute to the myelodysplastic 
syndrome in this patient, although an effect for the combination cannot be ruled out. It 
is also possible that secondary effects of previous treatment together with the presence 
of TP53 germline mutations may contribute to the development of myelodysplasia. 
 
Hypodiploidy and abnormalities of chromosomes 3, 5, 7 and 17 are associated with 
secondary leukemias [33– 36]. The 11q23 abnormality has also been reported, and is 
often associated with the appearance of epipodophyl-lotoxin-related leukemias [31]. 
Cytogenetic abnormalities occurring in our patient were analogous to those found in 
patients with leukemia that follows the use of alkylating agents [4,24,29]. Molecular 
analysis of bone marrow blasts performed in our patient, and the presence of 
cytogenetic abnormalities of chromosome 17 suggest that TP53 mutations could play an 
important role in the development of leukemia. Recent investigations have 
demonstrated that TP53 gene is important in maintaining genomic integrity [37]. The 
accumulation of cytogenetic abnormalities in the myelodysplastic marrow cells of our 
patient could reflect the high mutation rate that results when there is an absence or a 
functional alteration of wild-type TP53 as the cellular sensor of damaged DNA. 
 
Clinically, secondary leukemias have several features: a latency period of 3 to 6 years 
after treatment, a preleukemic presentation as myelodysplastic syndrome and a poor 
response to conventional chemotherapy [33]. A low remission rate and a very poor 
survival are observed among patients with secondary leukemia [33,34]. Some features 
have been associated with shorter survival: karyotypic abnormalities other than 
balanced translocations or inversion of chromosome 16, age of 65 or older and marrow 
blasts 5% or more [33]. TP53 mutations have become a strong prognostic factor in 
secondary leukemias because these mutations have been recently implicated as one of 
the causes of resistance to chemotherapy [38]. Our patient had an ominous prognosis, 
but complete remission was achieved with intensive chemotherapy. Ultimately, the 
patient died, despite the fact that an allogeneic peripheral blood progenitor cell 
transplantation was performed. 
 
In conclusion, we report the case of an acute leukemia preceded by a myelodysplastic 
phase after treatment for chondroblastic osteosarcoma. Cytogenetic and molecular 
studies performed on different tissues showed that tumoural development could be 
related, in this patient, with TP53 mutations. This observation supports the proposal by 
some authors that children with osteosarcoma should be considered for predictive 
testing for TP53 mutations [8]. 
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Figure 1. Sequencing showing the complex mutant pattern of TP53 exon 7: one allele 
(1) presents deletion of a ‘‘C’’ that causes a shift in the coding frame and the other 
allele (2) has a tandem transition ‘‘CC’’ to ‘‘TT’’ that changes the codified amino acid 
at position 250. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Partial G-banded karyotype showing the translocation t(3;6)(q21,p21). 
Arrows indicate abnormal chromosomes. 
 
 
 
 
 
 
 
 
